4.8 Article

A novel concept in antiangiogenic and antitumoral therapy: multitarget destabilization of short-lived mRNAs by the zinc finger protein ZFP36L1

期刊

ONCOGENE
卷 29, 期 45, 页码 5989-6003

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2010.341

关键词

tumor angiogenesis; VEGF; ZFP36L1; tristetraprolin; mRNA stability; multitarget therapy

资金

  1. Institut National de la Sante et de la Recherche Medicale (INSERM) [U878]
  2. Commissariat a l'Energie Atomique (iRTSV/LAPV)
  3. Institut du Cancer (INCa)
  4. Canceropole Rhone-Alpes (CLARA)
  5. Groupement des Entreprises Francaises pour la Lutte contre le Cancer (GEFLUC)-Comite Dauphine -Savoie
  6. Association pour la Recherche sur le Cancer
  7. Fondation pour la Recherche Medicale

向作者/读者索取更多资源

Angiogenesis inhibitors have shown clinical benefits in patients with advanced cancer, but further therapeutic improvement is needed. We have previously shown that the zinc finger protein 36, C3H type-like 1 (ZFP36L1) enhances vascular endothelial growth factor (VEGF) mRNA decay through its interaction with AU-rich elements within VEGF 3'-untranslated region. In this study, we evaluated the possibility to develop an antiangiogenic and antitumoral strategy using the mRNA-destabilizing activity of ZFP36L1. We engineered a cell-penetrating ZFP36L1, by fusing it to the protein transduction domains (PTDs) TAT derived from HIV, or the polyarginine peptides R7 or R9. PTD-ZFP36L1 fusion proteins were expressed in bacterial cells and affinity-purified to homogeneity. TAT-, R7- and R9-ZFP36L1 were efficiently internalized into living cells and decreased both endogenous VEGF mRNA half-life and VEGF protein levels in vitro. Importantly, a single injection of R9-TIS11b fusion protein into a high-VEGF expressing tissue in vivo (in this study, the mouse adrenal gland) markedly decreased VEGF expression. We further evaluated the effect of R9-ZFP36L1 on tumor growth using Lewis Lung Carcinoma (LL/2) cells implanted subcutaneously into nude mice. Intratumoral injection of R9-ZFP36L1 significantly reduced tumor growth and markedly decreased the expression of multiple angiogenic and inflammatory cytokines, including VEGF, acidic fibroblast growth factor, tumor necrosis factor alpha, interleukin (IL)-1 alpha and IL-6, with a concomitant obliteration of tumor vascularization. These findings indicate that R9-ZFP36L1 fusion protein may represent a novel antiangiogenic and antitumoral agent, and supports the emerging idea that modulation of mRNA stability represents a promising therapeutic approach to treat cancer. Oncogene (2010) 29, 5989-6003; doi:10.1038/onc.2010.341; published online 30 August 2010

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据